Abstract
Based on the structural analysis of tricyclic scaffolds as butyrylcholinesterase (BuChE) inhibitors, a series of pyrazolo[1,5-c][1,3]benzoxazin-5(5H)-one derivatives were designed, synthesized and evaluated for their acetylcholinesterase (AChE) and BuChE inhibitory activity. Compounds with 5-carbonyl and 7- or/and 9-halogen substitutions showed potential BuChE inhibitory activity, among which compounds 6a, 6c and 6g showed the best BuChE inhibition (IC50 = 1.06, 1.63 and 1.63 µM, respectively). The structure–activity relationship showed that the 5-carbonyl and halogen substituents significantly influenced BuChE activity. Compounds 6a and 6g were found nontoxic, lipophilic and exhibited remarkable neuroprotective activity and mixed-type inhibition against BuChE (Ki = 7.46 and 3.09 µM, respectively). Docking studies revealed that compound 6a can be accommodated into BuChE via five hydrogen bonds, one Pi–Sigma interaction and three Pi–Alkyl interactions.
1. Introduction
Alzheimer’s disease (AD), characterized by progressive deterioration of memory and other cognitive impairments, is a chronic neurodegenerative diseaseCitation1,Citation2. Forty-seven million people are living with dementia worldwide according to World Alzheimer Report 2016, and this number will increase to more than 131 million by 2050Citation3. In the past decades, various pathogenesis hypothesis of AD have been proposed, such as cholinergic dysfunction, β-amyloid oligomerisation, tau-protein hyperphosphorylation and oxidative stress, etcCitation4–8. Among them, cholinergic dysfunction hypothesis was the most effective therapeutic strategy. Thus, one efficient approach to treat AD is to restore the level of acetylcholine using cholinesterases (ChEs), such as acetylcholinesterase (AChE) and butyrlcholinesterase (BuChE) inhibitorsCitation9–11. It has been found that amyloid protein plaques can be caused by ChEs and can be decreased by ChEs inhibitorsCitation12. Currently, marketed AD drugs are mainly ChEs inhibitors rivastigmine, galantamine and donepezil. Thus, the search for new ChE inhibitors is still of great interestCitation13–17.
AChE inhibitors have been used for clinical AD treatments. AChE plays an important role in the hydrolysis of ACh in normal brain, while BuChE takes over the hydrolysis of ACh in the AChE deficient brainCitation18,Citation19. In the hippocampi of AChE deficient mice, levels of excessive ACh were alleviated by BuChE activityCitation20. In view of an increased level of BuChE and decreased level of AChE in the progressed AD, development of effective and selective BuChE inhibitor is of vital importanceCitation21. Besides, BuChE is associated with drug metabolism and detoxification, lipoprotein metabolism and diseases, etc. The crystal structures of two ChEs are very similar, containing a catalytic active site (CAS), a deep gorge and a peripheral anionic site (PAS)Citation22. Compared to AChE, a wider space of BuChE in acyl-binding site allows larger substrates to be recognised and hydrolyzedCitation23. The structural feature of BuChE provides a reasonable thought to design selective BuChE inhibitorsCitation24–29. Although there are some types of scaffolds with BuChE inhibition, selective BuChE inhibitors are far from abundanceCitation30.
The pyrazole scaffolds are pharmacologically active substances for drug discovery due to their excellent biological and pharmacological activitiesCitation31–33. In our recent works, several pyrazole-containing motifs were designed as potential telomerase inhibitors with anticancer activityCitation34–36, selective monoamine oxidase and/or ChE inhibitors for treating Alzheimer’s and Parkinson’s diseasesCitation37,Citation38. Furthermore, a series of pyrazole-containing tricyclic scaffolds were found as selective BuChE inhibitorsCitation39. hBuChE (PDB 1P0I)-targeted molecular docking showed that when the seven-membered benzoxazepine ring is replaced by a six-membered benzoxazine ring, the decreased volume may enhance its affinity with target protein (). Therefore, we synthesized a series of pyrazolo[1,5-c][1,3]benzoxazin-5(5H)-one derivatives, and evaluated for their cholinesterase inhibitory activity and the active compounds were used to study the preliminary mechanism.
Figure 1. The rational design in this study.
2. Materials and methods
2.1. Chemistry
All chemicals, reagents and solvents were purchased from commercial sources and used without further purification. Reactions were checked by thin-layer chromatography (TLC) on precoated silica gel plates (Qingdao Marine Chemical Factory, GF254); spots were visualized by UV at 254 nm. Melting points are determined on a XT4MP apparatus (Taike Corp., Beijing, China) and are not corrected. 1H NMR and 13C NMR spectra were recorded on Bruker AV-600 or AV-300 MHz instruments using DMSO-d6 and CDCl3 as solvent. Chemical shifts are reported in parts per million (δ) downfield from the signal of tetramethylsilane (TMS) as internal standards. Coupling constants are reported in Hz. The multiplicity is defined by s (singlet), d (doublet), t (triplet) or m (multiplet). High resolution mass spectra (HRMS) were obtained on an Agilent 1260-6221 TOF mass spectrometry.
2.2. General procedure for the synthesis of compounds (3a–3f)
A series of chalcones (1) were synthesized by Claisen–Schmidt condensation of aromatic methyl ketones and salicylaldehyde in alkali ethanol, which were then treated with excess hydrazine hydrate to afford respective pyrazolines (2) according to the referencesCitation38–40. Carbonyl diimidazole (CDI, or thiocarbonyl diimidazole, TCDI, 3.0 mmol) was added to CH2Cl2 (20 ml) solution of compound 2 (2.0 mmol), then the reaction mixture was stirred at room temperature until the disappearance of starting material (monitored by TLC). The reaction mixture was washed with water and brine, dried with anhydrous Na2SO4, filtrated and concentrated in vacuo. The residue was purified by chromatography on a silica gel column (petroleum/EtOAc, 1:1 → 1:2) to give title compounds 3a–3f. Compounds 3a–3f are known ones with no reports about bioactivityCitation40.
2.2.1. 2-Phenyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (3a)
White powder, yield: 26%; m.p. 200–202 °C; 1H NMR (300 MHz, CDCl3) δ 7.91–7.84 (m, 2H, Ar[sbond]H), 7.49–7.34 (m, 4H, Ar[sbond]H), 7.22 (m, 3H, Ar[sbond]H), 5.40 (dd, J = 12.9, 10.5 Hz, 1H, 10b-H), 3.83 (dd, J = 16.3, 10.4 Hz, 1H, 1-Ha), 3.48 (dd, J = 16.2, 13.1 Hz, 1H, 1-Hb). 13C NMR (75 MHz, CDCl3) δ 158.2 (C[dbond]O), 150.5 (C[dbond]N), 146.7 (C[sbond]O), 131.3, 130.5, 130.0, 129.0, 127.3, 125.2, 124.8, 122.8, 117.1, 57.6 (C-10b), 38.8 (C-1). TOF-HRMS: m/z [M + H]+ calcd for C16H13N2O2: 265.0972; found: 265.0979.
2.2.2. 2-Phenyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-thione (3b)
Light yellow powder, yield: 28%; m.p. 189–191 °C; 1H NMR (300 MHz, CDCl3) δ 7.92 (m, 2H, Ar[sbond]H), 7.56–7.38 (m, 4H, Ar[sbond]H), 7.32–7.21 (m, 3H, Ar[sbond]H), 5.37–5.26 (m, 1H, 10b-H), 3.94 (dd, J = 16.5, 10.1 Hz, 1H, 1-Ha), 3.55 (dd, J = 16.5, 12.4 Hz, 1H, 1-Hb). TOF-HRMS: m/z [M + H]+ calcd for C16H13N2O2: 281.0743; found: 281.0750.
2.2.3. 2-(4-Fluoro)phenyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (3c)
White powder, yield: 21%; m.p. 257–260 °C; 1H NMR (300 MHz, CDCl3) δ 7.92–7.82 (m, 2H, Ar[sbond]H), 7.43–7.22 (m, 3H, Ar[sbond]H), 7.19–7.10 (m, 3H), 5.41 (dd, J = 13.0, 10.4 Hz, 1H, 10b-H), 3.81 (dd, J = 16.2, 10.4 Hz, 1H, 1-Ha), 3.47 (dd, J = 16.2, 13.1 Hz, 1H, 1-Hb). TOF-HRMS: m/z [M + H]+ calcd for C16H12FN2O2: 283.0877; found: 283.0880.
2.2.4. 9-Chloro-2-(4-chloro)phenyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (3d)
White powder, yield: 32%; m.p. 206–208 °C; 1H NMR (300 MHz, CDCl3) δ 7.79 (d, J = 8.5 Hz, 2H, Ar[sbond]H), 7.43 (d, J = 8.5 Hz, 2H, Ar[sbond]H), 7.35 (dd, J = 8.7, 1.8 Hz, 1H, Ar[sbond]H), 7.23 (s, 1H, Ar[sbond]H), 7.14 (d, J = 8.7 Hz, 1H, Ar[sbond]H), 5.46–5.33 (m, 1H, 10b-H), 3.80 (dd, J = 16.3, 10.5 Hz, 1H, 1-Ha), 3.46 (dd, J = 16.3, 13.0 Hz, 1H, 1-Hb). TOF-HRMS: m/z [M + H]+ calcd for C16H11Cl2N2O2: 333.0192; found: 333.0196.
2.2.5. 9-Chloro-2-(4-methyl)phenyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (3e)
White powder, yield: 28%; m.p. 186–188 °C; 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 8.1 Hz, 2H, Ar[sbond]H), 7.34 (dd, J = 8.6, 2.1 Hz, 1H, Ar[sbond]H), 7.27 (s, 1H, Ar[sbond]H), 7.24 (d, J = 4.4 Hz, 2H, Ar[sbond]H), 7.13 (d, J = 8.7 Hz, 1H, Ar[sbond]H), 5.41–5.31 (m, 1H, 10b-H), 3.80 (dd, J = 16.2, 10.4 Hz, 1H, 1-Ha), 3.45 (dd, J = 16.2, 13.0 Hz, 1H, 1-Hb), 2.41 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 158.3 (C[dbond]O), 150.5 (C[dbond]N), 146.7 (C[sbond]O), 141.9, 129.9, 129.7 (2C), 127.7, 127.3 (2C), 125.2, 124.8, 122.8, 117.1, 57.5 (C-10b), 38.8 (C-1), 21.7 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C17H14ClN2O2: 313.0738; found: 313.0743.
2.2.6. 2–(4-Methyl)phenyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (3f)
White powder, yield: 20%; m.p. 186–189 °C; 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 8.1 Hz, 2H, Ar[sbond]H), 7.41–7.32 (m, 1H, Ar[sbond]H), 7.26–7.21 (m, 4H, Ar[sbond]H), 7.17 (d, J = 8.1 Hz, 1H, Ar[sbond]H), 5.36 (dd, J = 13.0, 10.4 Hz, 1H, 10b-H), 3.80 (dd, J = 16.2, 10.3 Hz, 1H, 1-Ha), 3.43 (dd, J = 16.2, 13.1 Hz, 1H, 1-Hb), 2.39 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 158.3 (C[dbond]O), 149.1 (C[dbond]N), 146.2 (C[sbond]O), 142.1, 130.3, 130.0, 129.7 (2C), 127.5, 127.3 (2C), 124.9, 124.4, 118.5, 57.3 (C-10b), 38.7 (C-1), 21.7 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C17H15N2O2: 279.1128; found: 279.1134.
2.3. General procedure for the synthesis of compounds (6a–6q)
A series of pyrazoline derivatives (5) were synthesized by similar synthesis procedure using salicylaldehyde in alkali acetone. CDI (or TCDI, 3.0 mmol) was added to a CH2Cl2 (20 ml) solution of compound 5 (2.0 mmol), then the reaction mixture was stirred overnight at room temperature. The reaction solution was washed with water and brine, dried with anhydrous Na2SO4, filtrated and concentrated in vacuo. The residue was purified by column chromatography (silica gel, petroleum/EtOAc, 1:1 → 1:2) to give title compounds 6a–6q.
2.3.1. 7,9-Dichloro-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (6a)
White powder, yield: 27%; m.p. 237–240 °C; 1H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 2.2 Hz, 1H, Ar[sbond]H), 7.03 (d, J = 1.2 Hz, 1H, Ar[sbond]H), 5.31–5.20 (m, 1H, 10b-H), 3.35 (dd, J = 16.8, 10.3 Hz, 1H, 1-Ha), 3.11 (dd, J = 16.7, 12.7 Hz, 1H, 1-Hb), 2.20 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 160.3 (C[dbond]O), 145.4 (C[dbond]N), 145.1 (C[sbond]O), 130.3, 130.1, 125.5, 123.34, 123.30, 57.2 (C-10b), 42.4 (C-1), 16.4 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H9Cl2N2O2: 271.0036; found: 271.0038.
2.3.2. 7,9-Dichloro-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-thione (6b)
White powder, yield: 35%; m.p. 230–233 °C; 1H NMR (300 MHz, CDCl3) δ 7.43 (d, J = 1.7 Hz, 1H, Ar[sbond]H), 7.04 (s, 1H, Ar[sbond]H), 5.25 (t, J = 10.9 Hz, 1H, 10b-H), 3.51 (dd, J = 17.1, 10.1 Hz, 1H, 1-Ha), 3.22 (dd, J = 17.0, 11.9 Hz, 1H, 1-Hb), 2.29 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 174.8 (C[dbond]S), 164.7 (C[dbond]N), 144.6 (C[sbond]O), 130.7, 130.4, 124.8, 123.0, 122.7, 57.4 (C-10b), 42.7 (C-1), 16.7 (CH3).TOF-HRMS: m/z [M + H]+ calcd for C11H9Cl2N2OS: 286.9807; found: 286.9806.
2.3.3. 7,9-Dibromo-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (6c)
White powder, yield: 30%; m.p. 229–232 °C; 1H NMR (300 MHz, CDCl3) δ 7.81–7.67 (m, 1H, Ar[sbond]H), 7.21 (dd, J = 2.1, 1.1 Hz, 1H, Ar[sbond]H), 5.26 (dd, J = 12.5, 10.4 Hz, 1H, 10b-H), 3.35 (dd, J = 16.9, 10.3 Hz, 1H, 1-Ha), 3.12 (dd, J = 16.8, 12.6 Hz, 1H, 1-Hb), 2.20 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 160.3 (C[dbond]O), 147.1 (C[dbond]N), 145.1 (C[sbond]O), 135.9, 126.88, 125.8, 117.5, 112.0, 57.1 (C-10b), 42.4 (C-1), 16.4 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H9Br2N2O2: 358.9025; found: 358.9023.
2.3.4. 7,9-Dibromo-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-thione (6d)
White powder, yield, 26%; m.p. 268–270 °C; 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 1.7 Hz, 1H, Ar[sbond]H), 7.21 (d, J = 0.8 Hz, 1H, Ar[sbond]H), 5.25–5.15 (m, 1H, 10b-H), 3.47 (dd, J = 17.1, 10.0 Hz, 1H, 1-Hb), 3.21 (dd, J = 16.2, 11.9 Hz, 1H, 1-Hb), 2.29 (s, 3H, CH3).13C NMR (75 MHz, CDCl3) δ 175.1 (C[dbond]S), 164.5 (C[dbond]N), 146.6 (C[sbond]O), 136.3, 126.7, 125.1, 118.2, 111.6, 57.5 (C-10b), 42.9 (C-1), 16.9 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H9Br2N2OS: 376.8776; found: 376.8777.
2.3.5. 9-Chloro-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (6e)
White powder, yield: 32%; m.p. 184–186 °C; 1H NMR (300 MHz, CDCl3) δ 7.31 (dd, J = 8.7, 2.4 Hz, 1H, Ar[sbond]H), 7.12 (dd, J = 2.4, 1.0 Hz, 1H, Ar[sbond]H), 7.09 (d, J = 8.8 Hz, 1H, Ar[sbond]H), 5.24 (dd, J = 12.6, 10.4 Hz, 1H, 10b-H), 3.34 (dd, J = 16.8, 10.3 Hz, 1H, 1-Ha), 3.11 (dd, J = 17.9, 12.7 Hz, 1H, 1-Hb), 2.19 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 159.9 (C[dbond]O), 149.1 (C[dbond]N), 146.1 (C[sbond]O), 130.2, 129.9, 124.9, 124.3, 118.5, 57.0 (C-10b), 42.5 (C-1), 16.4 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H10ClN2O2: 237.0425; found: 237.0430.
2.3.6. 9-Chloro-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-thione (6f)
Light yellow powder, yield: 28%; m.p. 220–222 °C; 1H NMR (300 MHz, CDCl3) δ 7.35 (dd, J = 8.7, 2.0 Hz, 1H, Ar[sbond]H), 7.18 (d, J = 8.7 Hz, 1H, Ar[sbond]H), 7.12 (d, J = 1.3 Hz, 1H, Ar[sbond]H), 5.28–5.12 (m, 1H, 10b-H), 3.49 (dd, J = 17.1, 10.0 Hz, 1H, 1-Ha), 3.21 (dd, J = 17.5, 12.5 Hz, 1H, 1-Hb), 2.29 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 176.1 (C[dbond]S), 164.7 (C[dbond]N), 148.3 (C[sbond]O), 130.9, 130.2, 124.7, 123.5, 118.0, 57.3 (C-10b), 42.9 (C-1), 16.8 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H10ClN2OS: 253.0197; found: 253.0201.
2.3.7. 9-Bromo-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (6g)
White powder, yield: 27%; m.p. 211–213 °C; 1H NMR (300 MHz, CDCl3) δ 7.46 (dd, J = 8.7, 1.7 Hz, 1H, Ar[sbond]H), 7.27–7.25 (m, 1H, Ar[sbond]H), 7.04 (d, J = 8.7 Hz, 1H, Ar[sbond]H), 5.24 (dd, J = 12.6, 10.4 Hz, 1H, 10b-H), 3.33 (dd, J = 16.8, 10.3 Hz, 1H, 1-Ha), 3.11 (dd, J = 17.9, 12.7 Hz, 1H, 1-Hb), 2.18 (d, J = 6.2 Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 159.8 (C[dbond]O), 149.6 (C[dbond]N), 146.0 (C[sbond]O), 132.9, 127.8, 124.8, 118.9, 117.5, 56.9 (C-10b), 42.5 (C-1), 16.4 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H10BrN2O2: 280.9920; found: 280.9925.
2.3.8. 9-Bromo-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-thione (6h)
Light yellow powder, yield: 31%; m.p. 245–247 °C; 1H NMR (300 MHz, CDCl3) δ 7.50 (dd, J = 8.7, 1.8 Hz, 1H, Ar[sbond]H), 7.27–7.25 (m, 1H, Ar[sbond]H), 7.14 (d, J = 8.7 Hz, 1H, Ar[sbond]H), 5.26–5.11 (m, 1H, 10b-H), 3.47 (dd, J = 17.1, 10.0 Hz, 1H, 1-Ha), 3.21 (dd, J = 18.1, 12.0 Hz, 1H, 1-Hb), 2.29 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 176.0 (C[dbond]S), 164.2 (C[dbond]N), 148.7 (C[sbond]O), 133.1, 127.5, 123.7, 118.3, 118.1, 57.0 (C-10b), 42.8 (C-1), 16.7 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H10BrN2OS: 296.9692; found: 296.9695.
2.3.9. 7-Bromo-9-chloro-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (6i)
White powder, yield: 29%; m.p. 228–231 °C; 1H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 2.2 Hz, 1H, Ar[sbond]H), 7.07 (s, 1H, Ar[sbond]H), 5.31–5.20 (m, 1H, 10b-H), 3.34 (dd, J = 16.8, 10.3 Hz, 1H, 1-Ha), 3.11 (dd, J = 16.3, 12.8 Hz, 1H, 1-Hb), 2.20 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 160.13 (C[dbond]O), 146.66 (C[dbond]N), 145.15 (C[sbond]O), 133.3, 130.5, 125.3, 123.9, 111.8, 57.2 (C-10b), 42.4 (C-1), 16.4 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H9BrClN2O2: 314.9530; found: 314.9537.
2.3.10. 7-Bromo-9-chloro-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-thione (6j)
White powder, yield: 30%; m.p. 248–250 °C; 1H NMR (300 MHz, CDCl3) δ 7.60 (d, J = 2.1 Hz, 1H, Ar[sbond]H), 7.07 (d, J = 1.1 Hz, 1H, Ar[sbond]H), 5.23 (t, J = 10.9 Hz, 1H, 10b-H), 3.49 (dd, J = 17.1, 10.1 Hz, 1H, 1-Ha), 3.21 (dd, J = 16.7, 12.2 Hz, 1H, 1-Hb), 2.29 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 175.0 (C[dbond]O), 165.0 (C[dbond]N), 146.0 (C[sbond]O), 133.4, 131.1, 124.7, 123.9, 111.1, 57.6 (C-10b), 42.8 (C-1), 16.9 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H9BrClN2OS: 330.9302; found: 330.9306.
2.3.11. 2-Methyl-7-methoxy-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (6k)
White powder, yield: 27%; m.p. 189–192 °C; 1H NMR (300 MHz, CDCl3) δ 7.12 (t, J = 8.0 Hz, 1H, Ar[sbond]H), 6.92 (d, J = 8.2 Hz, 1H, Ar[sbond]H), 6.69 (d, J = 7.7 Hz, 1H, Ar[sbond]H), 5.25 (dd, J = 12.5, 10.5 Hz, 1H, 10b-H), 3.89 (s, 3H, CH3), 3.32 (dd, J = 16.8, 10.3 Hz, 1H, 1-Ha), 3.10 (dd, J = 16.3, 13.3 Hz, 1H, 1-Hb), 2.18 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 159.7 (C[dbond]O), 148.0 (C[dbond]N), 146.3 (C[sbond]O), 139.9, 125.3, 123.9, 115.9, 112.7, 57.3 (C-10b), 56.4 (OCH3), 42.7 (C-1), 16.4 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C12H13N2O3: 233.0921; found: 233.0925.
2.3.12. 2-Methyl-7-methoxy-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-thione (6l)
Light yellow powder, yield: 28%; m.p. 217–219 °C; 1H NMR (300 MHz, CDCl3) δ 7.16 (t, J = 8.0 Hz, 1H, Ar[sbond]H), 6.95 (d, J = 8.2 Hz, 1H, Ar[sbond]H), 6.68 (d, J = 7.7 Hz, 1H, Ar[sbond]H), 5.25–5.10 (m, 1H, 10b-H), 3.91 (s, 3H, CH3), 3.47 (dd, J = 17.1, 10.0 Hz, 1H, 1-Ha), 3.20 (dd, J = 17.1, 12.1 Hz, 1H, 1-Hb), 2.28 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 176.3 (C[dbond]O), 164.5 (C[dbond]N), 147.4 (C[sbond]O), 139.3, 126.1, 123.1, 115.6, 112.9, 57.5 (C-10b), 56.4 (OCH3), 43.1 (C-1), 16.8 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C12H13N2O2S: 249.0692; found: 249.0694.
2.3.13. 2,9-Dimethyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (6m)
White powder, yield: 31%; m.p. 174–177 °C; 1H NMR (300 MHz, CDCl3) δ 7.12 (d, J = 8.3 Hz, 1H, Ar[sbond]H), 7.01 (d, J = 8.3 Hz, 1H, Ar[sbond]H), 6.91 (s, 1H, Ar[sbond]H), 5.29–5.15 (m, 1H, 10b-H), 3.32 (dd, J = 16.8, 10.2 Hz, 1H, 1-Ha), 3.09 (dd, J = 16.3, 13.3 Hz, 1H, 1-Hb), 2.34 (s, 3H, CH3), 2.18 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 159.7 (C[dbond]O), 148.3 (C[dbond]N), 146.8 (C[sbond]O), 134.8, 130.3, 125.1, 122.4, 116.7, 57.3 (C-10b), 42.6 (C-1), 20.9 (9-CH3), 16.4 (2-CH3). TOF-HRMS: m/z [M + H]+ calcd for C12H13N2O2: 217.0972; found: 217.0981.
2.3.14. 2,9-Dimethyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-thione (6n)
Light yellow powder, yield: 28%; m.p. 188–190 °C; 1H NMR (300 MHz, CDCl3) δ 7.17 (d, J = 8.3 Hz, 1H, Ar[sbond]H), 7.12 (d, J = 8.3 Hz, 1H, Ar[sbond]H), 6.91 (s, 1H, Ar[sbond]H), 5.20–5.10 (m, 1H, 10b-H), 3.44 (dd, J = 17.0, 9.9 Hz, 1H, 1-Ha), 3.20 (dd, J = 17.0, 12.2 Hz, 1H, 1-Hb), 2.36 (s, 3H, CH3), 2.28 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 177.0 (C[dbond]S), 164.4 (C[dbond]N), 147.8 (C[sbond]O), 135.8, 130.7, 124.9, 121.5, 116.4, 57.6 (C-10b), 43.1 (C-1), 21.1 (9-CH3), 16.9 (2-CH3). TOF-HRMS: m/z [M + H]+ calcd for C12H13N2OS: 233.0743; found: 233.0753.
2.3.15. 2-Methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (6o)
It is a known compound with no reports about bioactivityCitation41. Light yellow powder, yield: 32%; m.p. 162–164 °C; 1H NMR (600 MHz, CDCl3) δ 7.37–7.32 (m, 1H, Ar[sbond]H), 7.19 (td, J = 7.4, 3.0 Hz, 1H, Ar[sbond]H), 7.16–7.12 (m, 2H, Ar[sbond]H), 5.30–5.22 (m, 1H, 10b-H), 3.35 (dd, J = 16.7, 10.2 Hz, 1H, 1-Ha), 3.11 (dd, J = 16.1, 12.5 Hz, 1H, 1-Hb), 2.19 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 159.8 (C[dbond]O), 150.5 (C[dbond]N), 146.6 (C[sbond]O), 129.8, 125.1, 124.8, 122.8, 117.0, 57.2 (C-10b), 42.6 (C-1), 16.4 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H11N2O2: 203.0815; found: 203.0817.
2.3.16. 2-Methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-thione (6p)
Light yellow powder, yield: 34%; m.p. 218–220 °C; 1H NMR (300 MHz, CDCl3) δ 7.39 (t, J = 7.6 Hz, 1H, Ar[sbond]H), 7.25 (dd, J = 7.6, 4.5 Hz, 2H, Ar[sbond]H), 7.13 (d, J = 7.8 Hz, 1H, Ar[sbond]H), 5.28–5.14 (m, 1H, 10b-H), 3.49 (dd, J = 17.1, 9.9 Hz, 1H, 1-Ha), 3.21 (dd, J = 16.9, 12.3 Hz, 1H, 1-Hb), 2.29 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 176.6 (C[dbond]S), 164.7 (C[dbond]N), 149.7 (C[sbond]O), 130.2, 125.8, 124.7, 121.8, 116.5, 57.5 (C-10b), 43.0 (C-1), 16.8 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H11N2OS: 219.0587; found: 219.0590.
2.3.17. 7-Bromo-2-methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one (6q)
White powder, yield: 30%; m.p. 218–221 °C; 1H NMR (300 MHz, CDCl3) δ 7.60–7.51 (m, 1H, Ar[sbond]H), 7.06 (dd, J = 8.6, 5.3 Hz, 2H, Ar[sbond]H), 5.34–5.21 (m, 1H, 10b-H), 3.37 (dd, J = 16.8, 10.3 Hz, 1H, 1-Ha), 3.11 (dd, J = 16.7, 12.8 Hz, 1H, 1-Hb), 2.19 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 160.2 (C[dbond]O), 147.7 (C[dbond]N), 145.6 (C[sbond]O), 133.7, 125.9, 124.4, 123.9, 111.0, 57.4 (C-10b), 42.5 (C-1), 16.4 (CH3). TOF-HRMS: m/z [M + H]+ calcd for C11H10BrN2O2: 280.9920; found: 280.9918.
2.4. AChE/BuChE activity assays
Enzymatic activity assays were performed on AChE from electric eel (C3389-500UN; Sigma) and BuChE from equine serum (C4290-1KU; Sigma), according to Ellman’s method with light modificationCitation42. The experiment was performed in 48-well plates in a final volume of 500 µl. Each well contained 0.036 U/ml of EeAChE or eqBuChE, and 0.1 M pH = 8 phosphate buffer. They were incubated for 20 min at different concentrations of test compound at 37 °C. Then 0.35 mM acetylthiocholine iodide (ATCh; A5751-1G; Sigma) or 0.5 mM butyrylthiocholine iodide (20820-1G; Sigma) and 0.35 mM 5,5′-ditiobis-2-nitrobenzoico (DTNB; D8130-1G; Sigma) were added. The DTNB produced the yellow anion 5-thio-2-nitrobenzoic acid along with the enzymatic degradation of acetylthiocholine or butyrylthiocholine. The absorbance of each assay was measured at 410 nm after 20 min in a Biotek Synergy HTX Multi-Mode reader. The IC50 values were calculated graphically from inhibition curves (log inhibitor concentration vs percent of inhibition). A control experiment was performed under the same conditions without inhibitor and the blank contained buffer, DMSO, DTNB and substrate.
2.5. Kinetic studies of eqBuChE inhibition
Kinetic studies were performed with the same test conditions, using six concentrations of substrate (from 0.1 to 1 mM) and four concentrations of inhibitor (0–20 µM). The kinetic type of enzyme inhibition was obtained through the modified Ellman’s method and Lineweaver–Burk secondary plotsCitation43. Apparent inhibition constants and kinetic parameters were calculated within the “Enzyme kinetics” module of Prism 5.
2.6. Cytotoxicity assays
PC12 cells were used to evaluate cell cytotoxicity by methyl thiazolyl tetrazolium (MTT) assay. PC12 cells were cultured in DMEM containing 10% fetal bovine serum, 100 µg/ml streptomycin and 100 units/ml penicillin at 37 °C in a 5% CO2 humidified atmosphere, and inoculated at 1 × 104 cells per well in 96-well plate. After cultured for 24 h, the cells were treated with different concentration of compounds in DMEM for 24 h. Then 20 µl of 0.5 mg/ml MTT reagent was added into the cells and incubated for 4 h. After 4 h, cell culture was removed and then 150 µl DMSO was added to dissolve the formazan. The optical density was measured at 570 nm (OD570). Cell viability was calculated from three independent experiments. OD570 of formazan in blank group was set as 100% of viability. Cell viability (%) = compound (OD570)/blank (OD570) × 100%.
Blank: cultured with fresh medium only.
Compound: treated with compounds or donepezil.
2.7. Neuroprotective effect
The differentiated PC12 cells and oxidative agent H2O2 were used as in vitro model to assess neuronal differentiation and neurobiochemical and neurobiological propertiesCitation39,Citation44. Differentiated PC12 cells were incubated with different concentrations of compounds 6a and 6g for 3 h before treatment with H2O2 (300 µM). Cell viability was measured after 24 h using MTT method. Briefly, 20 µL of 0.5 mg/ml MTT reagent was added into the cells and incubated for 4 h. After 4 h, cell culture was removed and then 150 µl DMSO was added to dissolve the formazan. OD570 value was measured at 570 nm on the Biotek Synergy HTX Multi-Mode reader. Results were adjusted by OD570 value in the blank.
2.8. Log P assessment
Log P, defined as the logarithm of octanol–water partition coefficient, is an important parameter to evaluate lipophilicity of compoundsCitation45. It can be calculated by determining the concentration of compound in octanol phase and water phase until the partition equilibrium was completed. In this work, log P of title compounds was measured by the shake flask method with slight modification. PBS (pH = 7.4) was used as the water. Both the octanol and the aqueous phase were saturated with each other before use. The assay mixture containing test compounds was shaken at 37 °C. After 24 h, the mixture was centrifuged at 4,000 rpm for 30 min, followed by the measurement with UV spectrophotometer. Experiments were conducted in triplicate and log p values were calculated.
2.9. Molecular docking study
In order to further understand SAR, based on the X-ray crystal structure of human BuChE (hBuChE PDB ID: 1P0I), molecular docking was performed on the binding model using the Discovery Studio 2017R2 softwareCitation22,Citation23. A structure based in silico procedure was applied to discover the binding modes of the active compounds at BuChE enzyme active site. The CDOCKER of Discovery Studio 2017R2 (DS) was conducted to explain SAR of series compounds and further guide the design of more effective and specific BuChE inhibitors. The ligand binding to the crystal structure of hBuChE (PDB ID: 1P0I) was selected as template. The target enzyme was prepared with Prepare Protein of DS to ensure the integrity of target. The ligand was processed by Full Minimization of the Small Molecular in DS. Then title compounds were docked into the active site of protein using CDOCKER. The view results of docking were extracted after the program running end, each docking result was analyzed for interaction and their different pose. The binding energies of most potent compounds were clearly observed and tabulated in Table 2. The lowest -CDOCKER_INTERACTION_ENERGY values of those poses were regarded as the most stable and picked to analyze binding interactions with target enzyme visualized.
3. Results and discussion
3.1. Chemistry
According to recent worksCitation37–39, pyrazolo[1,5-c][1,3]benzoxazepin-5(5H)-one scaffolds (3a–3f and 6a–6q, as shown in ) were synthesized by the protocol outlined in Schemes 1 and 2. The intermediate 2-pyrazolines (2 and 5) were synthesized through the cyclization reaction of excess hydrazine hydrate with the styrene ketones, which were obtained from Claisen–Schmidt condensation. The title compounds 3 and 6 were respectively synthesized by the intramolecular coupled reaction of compounds 2 and 5 using carbonyl diimidazole (or thiocarbonyl diimidazole) as the couplant in CH2Cl2. The total yield was 20%–35%.
Scheme 1. Synthesis of compounds 3a–3f. Reagents and conditions: (i) 40% NaOH solution, EtOH, 60 °C; (ii) N2H4·H2O, EtOH, reflux; (iii) N,N′-carbonyldiimidazole or 1,1′-thiocarbonyldiimidazole, CH2Cl2, r.t.
Scheme 2. Synthesis of compounds 6a–6q. Reagents and conditions: (iv) 40% NaOH solution, 60 °C; (v) N2H4·H2O, EtOH, reflux; (vi) N,N′-carbonyldiimidazole or 1,1′-thiocarbonyldiimidazole, CH2Cl2, r.t.
Table 1. Chemical structures of compounds 3a–3f and 6a–6q and their inhibitory activities against EeAChE and eqBuChETable Footnotea
3.2. Biological activity
The inhibitory activities of title compounds against AChE and BuChE were assessed by modified Ellman’s method. The IC50 values were obtained and compared to the reference donepezil, a selective AChE inhibitor, which was the only one of four FDA-approved AChEIs. The IC50 values of all synthesized compounds against EeAChE and eqBuChE are summarized in .
According to the biological activity results, 23 tricyclic compounds showed inhibitory activities against cholinesterases. Compared to the reference donepezil, some compounds showed potent inhibitory activity against BuChE, but only moderate against AChE. From , it was obvious from the data that compounds 6a, 6c and 6g exhibited the best activities against BuChE with IC50 values of 1.06, 1.63 and 1.63 µM, respectively, surpassing that of control donepezil (IC50 = 10.38 µM). On inspection of the chemical structures, it can be concluded that BuChE inhibitory activity was related to the substituent groups at C2, C5, C7 and C9 positions of benzoxazinone moiety. When carbonyl at C5 position was substituted by sulfur carbonyl, BuChE inhibitory activity significantly decreased. Further, for compounds with carbonyl at C5 position, halogen substituents at the benzene ring have great influence on the BuChE inhibition, for example, compounds 6a, 6c, 6e, 6g, 6i and 6q with 7- or/and 9-halogen substitutions at the benzene ring exhibited better in terms of potency than the corresponding compounds 6k, 6m and 6o with methyl or methoxyl substituents, except for compound 3a. Compound 6a with 7,9-dichloro substituents showed the best BuChE inhibitory activity (IC50 = 1.06 µM) than the non-halogen substituted compounds 6k and 6m (inhibition rate at 20 µM < 20%). The SAR was observed in our recent workCitation39. The dehydroevodiamine-derived tri- and tetracyclic compounds also showed potent inhibitory activity and selectivity towards BuChECitation30. The polycyclic scaffold could be used to design selective BuChE inhibitors.
3.3. Kinetic study of eqBuChE inhibition
The kinetic studies were carried out at three fixed inhibitor concentrations (5, 10 and 20 µM). As shown in , for compounds 6a and 6g, overlaid reciprocal Lineweaver–Burk plots showed that both slopes (decreased Vmax) and intercepts (higher Km) increase with the increase of inhibitor concentration, which trend is usually ascribed to a mixed-type inhibition. The dissociation constants Ki for compounds 6a () and 6d () were estimated to be 7.46 and 3.09 µM, respectively.
Figure 2. Lineweaver − Burk plots of esBChE inhibition kinetics of compounds 6a (A), 6g (B). The Lineweaver–Burk secondary plots of compounds 6a (C) and 6g (D). Reciprocals of enzyme activity (esBuChE) vs. reciprocals of substrate (butyrylthiocholine iodide) concentration in the presence of different concentrations (0−20 µM) of inhibitor. Inset: Concentrations used for inhibitor are coded with different graphic symbols.
3.4. Cytotoxicity assays and neuroprotective effect
The neuroprotective activity of compounds 6a, 6g and donepezil against oxidative stress-induced cell death in differentiated PC12 neurons was assayed. The differentiated PC12 cells were pretreated with three concentrations (10, 25 and 50 µM) for 3 h, before treatment with H2O2 (300 µM), and cell viability was measured after 24 h using MTT method. As shown in , Compounds 6a, 6g and donepezil at the test concentrations (1–50 µM) had no obvious cytotoxicity in PC-12 cells, and the relative cell viabilities of treated cells were all more than 90%. Neuroprotective activity of compounds 6a and 6g against eqBuChE was evaluated by subjecting PC12 cells to H2O2-induced damage. As shown in , compared to control group, the percent of cell viability was calculated. Compounds 6a and 6g exhibited remarkable neuroprotective activity at 25 µM (cell viability >70%, and p < .05 vs. H2O2 treatment alone).
Figure 3. Cytotoxicity of compounds 6a, 6g and donepezil tested at concentrations in the range 1–50 µM in PC12 cell lines for 24 h. Untreated cells were used as control. Results are expressed as percentage of cell survival vs. untreated cell (control) and shown as mean ± SD (n = 3).
Figure 4. Neuroprotective effect on PC12 cell lines of compounds 6a and 6g. After 24 h incubation at different concentration (25 and 50 µM) with H2O2 (300 µM). Untreated cells were used as control. Results represent mean ± SD (n = 3). Statistical significance was calculated using one-way ANOVA and Bonferroni post hoc tests. ###p < .001 compared with the control group; *p < .05 compared with H2O2 group.
3.5. Log P assessment
As a potential compound for treatment of AD, log P (octanol–water partition coefficient) was thought as an important physical and chemical parameter to predict the ability to cross blood brain barrier (BBB). The log P with optimum central nervous system (CNS) penetration was around 2.0 ± 0.7. The log P values of active compounds 6a, 6c and 6g were 1.50, 1.48 and 1.63, respectively, which indicated that the active compounds had sufficient lipophilicity to pass the BBB in vivo.
3.6. Molecular docking
The results of docking calculation in showed that compounds 6a–6q had good binding affinity to BuChE and their CDOCKER_INTERACTION_ENERGY had almost the same trend as the BuChE inhibitory activities, which further proved the correlation between BuChE inhibitory activity and binding energy. Especially, when carbonyl at C5 position was substituted by sulfur carbonyl, the binding energy significantly decreased.
Table 2. -CDOCKER_INTERACTION_ENERGY of title compounds 6a–6q and 1P0I
Among them, compound 6a had the maximum -CDOCKER_INTERACTION_ENERGY and highest activity, while compound 6b with lower energy exhibited lower activity. The 2D and 3D binding models of compound 6a and 6b with BuChE are depicted in . Compound 6a () was well accommodated into BuChE via five conventional hydrogen bonds between the C[dbond]O group and Gly116 (distance = 2.67 Å), Gly117 (distance = 1.98 Å), Ala199 (distance = 2.49 Å), Ser198 (distance = 2.17 Å), and between the N atom and Gly116 (distance = 2.67 Å); three carbon hydrogen bond interactions between the C[dbond]O group and CH2 group of Ser198 and Gly117, and between the N atom and the CH2 group of Ser198; one Pi–Sigma interaction between benzene ring and the aromatic ring of Phe329; one Alkyl interaction between 7-Cl and the end group of Val288; three Pi–Alkyl interactions between 2-CH3 and the end group of Trp82, His438 and between 9-Cl and the end group of Tyr332. However, compound 6b () could also be accommodated into BuChE via one hydrogen bond between the O atom and Gly116 (distance = 2.67 Å); one Amide–Pi Stacked interaction between benzene ring and the amide of Gly116; one Pi–Pi shaped interaction between benzene ring and the aromatic ring of Phe329; two Alkyl interactions between 9-Cl and the end group of Val288, Leu286; three Pi–Alkyl interactions between 9-Cl and the end group of Trp231, and between 7-Cl and the end group of His438. Furthermore, the H-bonds surface of compound 6a and BuChE is also depicted in . The above results, along with the biological assay data, suggested that compound 6a possessed the best inhibitory activity, which will help us carry out the next structure optimization.
Figure 5. (A,C) 3D mode of interaction of compounds 6a and 6b and BuChE (PDB code: 1P0I) analysed by Discovery Studio 2017R2. Conventional hydrogen bond and carbon hydrogen bond and alkyl as well as Pi–alkyl are shown by green, light green and pink, respectively. (B,D) Two dimensional mode of interaction of compounds 6a and 6b and BuChE (PDB code: 1P0I) analysed by Discovery Studio 2017R2.
Figure 6. The H-Bonds surface of compound 6a and BuChE (PDB code: 1P0I) analysed by Discovery Studio 2017R2.
4. Conclusions
Based on the structural analysis of BuChE-targeted tricyclic scaffolds, we reported design and synthesis of a series of tricyclic pyrazolo[1,5-c][1,3]benzoxazin-5(5H)-one derivatives and evaluated in vitro AChE and BuChE activities. Compounds with 5-carbonyl and 7- or/and 9-halogen substitutions showed potent BuChE inhibitory activity, among them, compounds 6a, 6c and 6g showed the best BuChE inhibition (IC50 = 1.06, 1.63 and 1.63 µM, respectively). The SARs analysis showed that (i) BuChE inhibitory activity significantly decreased for compounds with 5-sulfurcarbonyl; (ii) compounds bearing 5-carbonyl and halogen substituents at the benzene ring had better BuChE inhibitory activity; (iii) the volumes of the substituted groups at the C2 position have influences for the BuChE activity. Kinetic studies revealed that compounds 6a and 6g showed a mixed-type inhibition against BuChE (Ki = 7.46 and 3.09 µM, respectively). The active compounds were found to be nontoxic at their effective concentrations and to have sufficient lipophilicity to pass the BBB in vivo. Compounds 6a and 6g had remarkable neuroprotective activity. Docking results showed that the synthesized compounds had same binding orientation within the active site of target enzyme. Compound 6a could be accommodated into BuChE via five hydrogen bonds with Gly116, Gly117, Ala199, Ser198 and Gly116, one Pi–Sigma interaction and three Pi–Alkyl interactions. The active compounds may be developed as selective BuChE inhibitors against progressive neurodegenerative disorder.
Supplemental Material
Download PDF (1.3 MB)Disclosure statement
No potential conflict of interest was reported by the authors.
Additional information
Funding
Related Research Data
References
- Mucke L. Neuroscience: Alzheimer’s disease. Nature 2009;461:895–7.
- Pivtoraiko VN, Abrahamson EE, Leurgans SE, et al. Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer’s disease. Neurobiol Aging 2015;36:12–19.
- Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement 2016;12:459–509.
- Masters CL, Selkoe DJ. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer Disease. Cold Spring Harb Perspect Med 2012;2:a006262.
- Avila J. Tau phosphorylation and aggregation in Alzheimer’s disease pathology. FEBS Lett 2006;580:2922–7.
- Müller ML, Bohnen NI. Cholinergic dysfunction in Parkinson’s disease. Curr Neurol Neurosci Rep 2013;13:377.
- Rosini M, Simoni E, Milelli A, et al. Oxidative stress in Alzheimer's disease: are we connecting the dots? J Med Chem 2014;57:2821–31.
- Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet 2016;388:505–17.
- Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002;109:1053–65.
- Mushtaq G, Greig NH, Khan JA, Kamal MA. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014;13:1432–9.
- Tonelli M, Catto M, Tasso B, et al. Multitarget therapeutic leads for Alzheimer's disease: quinolizidinyl derivatives of bi- and tricyclic systems as dual inhibitors of cholinesterases and β-Amyloid (Aβ) aggregation. ChemMedChem 2015;10:1040–53.
- Zhou D, Zhou W, Song JK, et al. DL0410, a novel dual cholinesterase inhibitor, protects mouse brains against Aβ-induced neuronal damage via the Akt/JNK signaling pathway. Acta Pharmacol Sin 2016;37:1401–12.
- Asadipour A, Alipour M, Jafari M, et al. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur J Med Chem 2013;70:623–30.
- Liu HR, Fan HQ, Gao XH, et al. Design, synthesis and preliminary structure–activity relationship investigation of nitrogen-containing chalcone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors: a further study based on Flavokawain B Mannich base derivatives. J Enzyme Inhib Med Chem 2016;31:580–9.
- Farina R, Pisani L, Catto M, et al. Structure-based design and optimization of multitarget-directed 2H-chromen-2-one derivatives as potent inhibitors of monoamine oxidase B and cholinesterases. J Med Chem 2015;58:5561–78.
- Bajda M, Więckowska A, Hebda M, et al. Structure-based search for new inhibitors of cholinesterases. Int J Mol Sci 2013;14:5608–32.
- Liu H, Liu L, Gao X, et al. Novel ferulic amide derivatives with tertiary amine side chain as acetylcholinesterase and butyrylcholinesterase inhibitors: the influence of carbon spacer length, alkylamine and aromatic group. Eur J Med Chem 2017;126:810–22.
- Appleyard ME, Smith AD, Berman P, et al. Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Brain 1987;110:1309–22.
- Norel X, Angrisani M, Labat C, et al. Degradation of acetylcholine in human airways: role of butyrylcholinesterase. Br J Pharmacol 1993;108:914–19.
- Brimijoin S, Tye S. Favorable impact on stress-related behaviors by modulating plasma butyrylcholinesterase. Cell Mol Neurobiol 2018;38:7–12.
- Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005;102:17213–18.
- Nicolet Y, Lockridge O, Masson P, et al. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003;278:41141–7.
- Brus B, Kosak U, Turk S, et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem 2014;57:8167–79.
- Csuk R, Albert S, Kluge R, et al. Resveratrol derived butyrylcholinesterase inhibitors. Arch Pharm (Weinheim) 2013;346:499–503.
- Košak U, Brus B, Knez D, et al. Development of an in-vivo active reversible butyrylcholinesterase inhibitor. Sci Rep 2016;6:39495.
- Gao XH, Zhou C, Liu HR, et al. Tertiary amine derivatives of chlorochalcone as acetylcholinesterase (AChE) and buthylcholinesterase (BuChE) inhibitors: the influence of chlorine, alkyl amine side chain and α,β-unsaturated ketone group. J Enzyme Inhib Med Chem 2017;32:146–52.
- Košak U, Brus B, Knez D, et al. The magic of crystal structure-based inhibitor optimization: development of a butyrylcholinesterase inhibitor with picomolar affinity and in vivo activity. J Med Chem 2018;61:119–39.
- Chen Y, Zhu J, Mo J, et al. Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer's disease. J Enzyme Inhib Med Chem 2018;33:290–302.
- Tasso B, Catto M, Nicolotti O, et al. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease. Eur J Med Chem 2011;46:2170–84.
- Li Q, Yang H, Chen Y, et al. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. Eur J Med Chem 2017;132:294–309.
- Secci D, Carradori S, Bolasco A, et al. Discovery and optimization of pyrazoline derivatives as promising monoamine oxidase inhibitors. Curr Top Med Chem 2012;12:2240–57.
- Alex JM, Kumar R. 4,5-Dihydro-1H-pyrazole: an indispensable scaffold. J Enzyme Inhib Med Chem 2014;29:427–42.
- Khan MF, Alam MM, Verma G, et al. The therapeutic voyage of pyrazole and its analogs: a review. Eur J Med Chem 2016;120:170–201.
- Wu XQ, Huang C, Jia YM, et al. Novel coumarin-dihydropyrazole thio-ethanone derivatives: design, synthesis and anticancer activity. Eur J Med Chem 2014;74:717–25.
- Qiang DZ, Shi JB, Song BA, et al. Novel 2H-chromen derivatives: design, synthesis and anticancer activity. RSC Adv 2014;4:5607–17.
- Chen YY, Wu XQ, Tang WJ, et al. Novel dihydropyrazole-chromen: design and modulates hTERT inhibition proliferation of MGC-803. Eur J Med Chem 2016;110:65–75.
- Tong X, Chen R, Zhang TT, et al. Design and synthesis of novel 2-pyrazoline-1-ethanone derivatives as selective MAO inhibitors. Bioorg Med Chem 2015;23:515–25.
- Chen R, Xiao J, Ni Y, et al. Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: design, synthesis, model and use as hMAO-B inhibitors. Bioorg Med Chem 2016;24:1741.
- Chen SC, Qiu GL, Li B, et al. Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: synthesis and biological evaluation as selective BuChE inhibitors. Eur J Med Chem 2018;147:194–204.
- Nawwar GAM. Tetrachloro-o-benzoquinone in organic synthesis: a novel synthetic route to pyrazolo[1,5-c][1,3]benzoxazines and 5,7-disubstituted 4-hydroxycoumarins. J Chem Res Synop 2010;23:5.
- Svetlik J, Pronayova N, Kubista J. Synthesis of some pyrazolo[1,5-c][1,3]benzoxazines and a new 5H-pyrazolo[1,5-c][1,3,2]benzoxazaphosphorine ring system. J Heterocyclic Chem 2005;42:1143–7.
- Ellman GL, Courtney KD, Andres V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
- Tamagno E, Bardini P, Obbili A, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002;10:279–88.
- Zha X, Lamba D, Zhang L, et al. Novel tacrine-benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer's disease: design, synthesis, biological evaluation, and X-ray crystallography. J Med Chem 2016;59:114–31.
- Tang WJ, Wang J, Tong X, et al. Design and synthesis of celastrol derivatives as anticancer agents. Eur J Med Chem 2015;95:166–73.